249 related articles for article (PubMed ID: 12798711)
1. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
Tunuguntla R; Ripley D; Sang QX; Chegini N
Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
[TBL] [Abstract][Full Text] [Related]
2. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.
Graesslin O; Cortez A; Fauvet R; Lorenzato M; Birembaut P; Daraï E
Ann Oncol; 2006 Apr; 17(4):637-45. PubMed ID: 16407419
[TBL] [Abstract][Full Text] [Related]
3. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium.
Freitas S; Meduri G; Le Nestour E; Bausero P; Perrot-Applanat M
Biol Reprod; 1999 Oct; 61(4):1070-82. PubMed ID: 10491646
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding.
Chegini N; Rhoton-Vlasak A; Williams RS
Fertil Steril; 2003 Sep; 80(3):564-70. PubMed ID: 12969699
[TBL] [Abstract][Full Text] [Related]
5. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors.
Hickey M; Crewe J; Mahoney LA; Doherty DA; Fraser IS; Salamonsen LA
J Clin Endocrinol Metab; 2006 Aug; 91(8):3189-98. PubMed ID: 16684831
[TBL] [Abstract][Full Text] [Related]
7. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
[TBL] [Abstract][Full Text] [Related]
8. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.
Ripley D; Tunuguntla R; Susi L; Chegini N
Int J Gynecol Cancer; 2006; 16(5):1794-800. PubMed ID: 17009974
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay.
Mizumoto H; Saito T; Ashihara K; Nishimura M; Takehara M; Tanaka R; Ito E; Kudo R
Life Sci; 2002 Jun; 71(3):259-73. PubMed ID: 12034345
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
13. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
14. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Am J Clin Pathol; 2000 Sep; 114(3):402-11. PubMed ID: 10989641
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland.
Nagel H; Laskawi R; Wahlers A; Hemmerlein B
Histopathology; 2004 Mar; 44(3):222-31. PubMed ID: 14987225
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture.
Park YH; Ryu HS; Choi DS; Chang KH; Park DW; Min CK
Int J Gynecol Cancer; 2003; 13(1):53-60. PubMed ID: 12631221
[TBL] [Abstract][Full Text] [Related]
17. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.
Graesslin O; Cortez A; Uzan C; Birembaut P; Quereux C; Daraï E
Int J Gynecol Cancer; 2006; 16(5):1911-7. PubMed ID: 17009991
[TBL] [Abstract][Full Text] [Related]
18. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
20. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
